Lu Peng sold $1.0M of PHVS

Lu Peng (Chief Medical Officer) sold 29,700 shares of Pharvaris N.V. (PHVS) at an average of $34.30 ($34.00–$35.09, $1.02M total) across 3 trades over 2026-06-25 to 2026-06-26 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Lu Peng
Published Jun 29, 2026, 10:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 29, 2026, 10:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PHVS
Neutral
medium confidence
Mentioned
$PHVS
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PHVSNeutralLow
01

Why it matters

Traders may monitor for follow-on insider activity or correlate with upcoming company catalysts, but the filing alone is not a fundamental change.

02

Market read

A single officer sale totaling ~$1.02M is disclosed; likely modest sentiment impact rather than a thesis-changing event.

03

What to watch

The disclosure does not state tax, diversification, or personal liquidity needs; without context, interpreting directionally is unreliable.

Relevance 5/10Novelty 4/10Timing: Filed after-hours on 2026-06-29; relevant for next-session sentiment/positioning.

Background

The article is an SEC Form 4 insider transaction: CMO Lu Peng sold PHVS shares (open-market sale) during 2026-06-25 to 2026-06-26 under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$PHVSNeutralMedium confidence
Context

Pharvaris N.V. (PHVS) disclosed via Form 4 that CMO Lu Peng sold 29,700 shares in open-market transactions under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and short-lived.

Evidence & confidence

The filing is an open-market sale by an officer with an explicit pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

No direct sector read-through; this is company-specific insider transaction data.

None indicated; US-listed trading impact only via sentiment.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still coincide with periods of reduced near-term upside expectations.

Key entities

  • Pharvaris N.V.

    Company that issued the Form 4 insider transaction for PHVS.

  • Lu Peng

    Chief Medical Officer who executed open-market sales under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PHVSMed

Pharvaris reports Q3 results

Pharvaris reported a Q3 EPS of -$0.67, with cash reserves of €283M as of September 30, 2026, down from €292M at year-end 2025. The company's net loss widened to €47.4M, up from €37.1M year-over-year. Recently, Pharvaris presented at healthcare conferences and announced positive late-stage trial results for its hereditary angioedema drug, leading to an upgrade by BofA to 'Buy'.

$PHVSMedAI 8/10

Pharvaris (PHVS) Reports Q3 Results After Phase 3 Milestone

Pharvaris (PHVS) reported Q3 2026 results, highlighting FDA review of deucrictibant IR NDA with a 2027 PDUFA date. Phase 3 study data for deucrictibant XR expected in 1Q2027. NDA submission for deucrictibant XR in AE-BK attacks planned for 1H2027. Cash position of €283M as of Q3 2026. No financial figures provided for Q3.